drugset / Trial / NCT00316628

Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

NCT00316628

Phase 2 Completed 50 enrolled Novartis Novartis Vaccines · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.

Timeline

Start
2005-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine Intramuscular

Indications